DexCom, Inc. (DXCM) Fair Value 2026

DXCM · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.2 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (6/100)

Quick Summary — As of 2026-08-27, DexCom, Inc. (DXCM) trades at $89.29, versus a $47.85 median fair value across its 9 active models — 46.4% below the current price. QOC: 9.2/10. Value Trap Risk: 6/100 (SAFE). 9/13 models active. Within that set, the Bayesian DCF component alone returns $50.38.

Key Facts

Ticker
DXCM
Price
$89.29
Quality Score
9.2/10
Value Trap Risk
6/100
Models Active
9/13
Last Updated
Strength: Quality Score of 9.2/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Is DexCom, Inc. (DXCM) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, DexCom, Inc. (DXCM) appears overvalued as of : the median of 9 independent fair value estimates is $47.85, 46.4% below the current price of $89.29. Estimates range from $13.37 to $93.78. DXCM scores 9.2/10 on fundamental quality and 6/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. DXCM’s -46.4% gap is wider than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy DexCom, Inc. Stock in 2026? →

What Fair Value Does Each Model Give DXCM?

9 Intrinsic Value Models vs. Current Price ($89.29)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $50.38 -43.6%
Intrinsic · High Conviction
 $13.37 -85.0%
Ensemble · Medium Conviction
 $41.32 -53.7%
Scenario · High Conviction
 $59.58 -33.3%
Unlock the Full Matrix

Access 5 additional models including EROIC Spread, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is DXCM's Fair Value Range?

Spread across 9 independent models · $13.37 to $93.78

CirclFi's 9 active models place DexCom, Inc. (DXCM) between $13.37 and $93.78 per share, a spread of 168% of the median. The median of that range — $47.85 — is the fair value CirclFi publishes for DXCM, against a current price of $89.29.

Low · EPVHigh · Regime Cross
$13.37median $47.85$93.78
Where the range comes from
Most bearish modelEarnings Power Value (EPV)$13.37
Most bullish modelRegime Cross-Sectional$93.78
Model agreement1 bullish · 8 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for DXCM. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on DXCM, not a CirclFi price target. How each model works →

What Is DexCom, Inc. (DXCM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, DexCom, Inc.'s intrinsic value is estimated at $47.85. Trading at its current price of $89.29, the valuation engine raises significant caution: 8 of 9 models flag downside risk, projecting a median implied return of -46.4%. The most optimistic model, Regime Cross, places fair value at $93.78 (+5.0%), while EPV — the most conservative — estimates $13.37 (-85.0%). This +90.1% gap reflects genuine analytical uncertainty about DexCom, Inc.'s intrinsic worth. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About DXCM?

9 of 13 models are currently active for DXCM. Of these, 1 model suggests upside while 8 models suggest overvaluation. Taken together, their median fair value for DXCM is $47.85 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $50.38 on its own, implying -43.6% downside from the current price. See which stocks rank higher →

How Does DXCM Rank in Medical Devices?

Among 157 Medical Devices stocks, DXCM ranks #4 by Quality of Company score. CirclFi's QOC score of 9.2/10 evaluates 32 fundamental signals. A score of 9.2 places DXCM in the top tier.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to pharmaceutical industry businesses. For DexCom, Inc., metrics like biosimilar competition timeline provide important context that general-purpose valuation models may underweight.

Is DXCM a Value Trap?

CirclFi's Value Trap algorithm assigns DXCM a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for DexCom, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, DexCom, Inc. scores 9.2 out of 10 on our 32-signal quality assessment, a elite rating that ranks among the highest-quality businesses in our coverage universe. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +90.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every DXCM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across DXCM's 9 active models, average confidence is 53%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy DexCom, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

9 related Medical Devices stocks with 13-model coverage

GMEDGlobus Medical, Inc.QOC 9.2UFPTUFP Technologies, Inc.QOC 9.2PODDInsulet CorporationQOC 9.6TMDXTransMedics Group, Inc.QOC 9.2IRMDIRADIMED CORPORATIONQOC 9.8ELMDElectromed, Inc.QOC 9.0PHGKoninklijke Philips N.V.QOC 7.1OMOutset Medical, Inc.QOC 6.1IVFINVO Fertility, Inc.QOC 5.1

Read investment analysis: GMED · UFPT · PODD · TMDX · IRMD · ELMD · PHG · OM · IVF

Which Other Stocks Have a Similar Quality Score to DXCM?

7 companies across all industries closest to DXCM’s Quality of Company score of 9.2/10.

UPWKUpwork Inc.QOC 9.2CWCurtiss-Wright CorporationQOC 9.2ACGLArch Capital Group Ltd.QOC 9.2IBPInstalled Building Products, Inc.QOC 9.2CDNSCadence Design Systems, Inc.QOC 9.2HESMHess Midstream LPQOC 9.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: UPWK · CW · ACGL · IBP · CDNS · HESM · NVDA

Where Does DXCM Sit in CirclFi's Medical Devices Rankings?

DXCM is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About DexCom, Inc.’s Valuation?

What is DexCom, Inc.'s intrinsic value in 2026?

CirclFi puts DexCom, Inc. (DXCM)'s intrinsic value at $47.85 — the median of 9 independent model estimates as of 2026-08-27, ranging from $13.37 to $93.78. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $50.38 on its own. The Quality of Company score is 9.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is DXCM overvalued or undervalued right now?

At $89.29, 1 of 9 active models suggest DXCM may be undervalued, while 8 indicate potential overvaluation. The median of all 9 fair value estimates is $47.85, 46.4% below the current price of $89.29 — a consensus view that DXCM is overvalued. The assessment depends on which methodology best fits DexCom, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 9.2 mean for DXCM?

DexCom, Inc.'s QOC of 9.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on DXCM?

CirclFi analyzes DXCM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on DXCM?

Of the 9 models currently active on DXCM, Regime Cross-Sectional is the most bullish at $93.78 per share, and Earnings Power Value (EPV) is the most bearish at $13.37. CirclFi's published fair value for DXCM is the median of that range, $47.85, not either extreme. The gap between the two ends equals 168% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is DXCM a value trap in 2026?

DexCom, Inc.'s Value Trap score is 6/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, DexCom, Inc. (DXCM) has a median fair value of $47.85 — 46.4% below the current price of $89.29 — as of 2026-08-27.” Source: circlfi.com/stock/DXCM/ · Methodology
Primary sources for this DXCM valuation
  • Financial statements: DexCom, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001093557) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for DXCM as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on DXCM.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for DXCM Unlock All 9 — $39/mo